Wellington Partners (Group)

https://www.wellington-partners.com

Twitter: @wellingtonvc

LinkedIn: https://www.linkedin.com/company/wellington-partners

Wellington Partners is a leading European Venture Capital firm investing in early- and growth stage life science companies. Wellington Partners is focused on investing in the most promising life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totalling EUR 1.0 billion, and more than EUR 400 million committed to Life Sciences, Wellington Partners has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, Wellington Partners has invested in 46 innovative life science companies, including Actelion (acquired by J&J), Definiens (acquired by AZ/Medimmune), Invendo (acquired by Ambu), MTM laboratories (acquired by Roche), Rigontec (acquired by MSD), Symetis (acquired by Boston Scientific), Immatics and AMBOSS. *

	Start	1998-01-01 established
	Today	Wellington Partners Venture Capital GmbH
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Strohmenger, Rainer (Wellington Partners Venture Capital 201303 General Partner)
	Person 2	Essig, Stuart M. (Wellington Partners 201303– Venture Partner before Integra Life Sciences CEO + Goldman Sachs)

	Region	München (Munich)
	Country	Germany
	Street	5 Türkenstr.
	City	80333 München
	Tel	+49-89-219941-0
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	1,000,000,000 (capital under management (2018) 2018-11-26)

		* Document for ï¿½About Sectionï¿½: Wellington Partners. (7/31/19). "Press Release: Wellington Partners Raises EUR 210 Million Life Science Fund".

		Record changed: 2021-02-21